M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator

Objectives Minimal residual disease status in multiple myeloma is an important prognostic biomarker. Recently, personalized blood-based targeted mass spectrometry (MS-MRD) was shown to provide a sensitive and minimally invasive alternative to measure minimal residual disease. However, quantification of MS-MRD requires a unique calibrator for each patient. The use of patient-specific stable isotope labelled (SIL) peptides is relatively costly and time-consuming, thus hindering clinical implementation. Here, we introduce a simplification of MS-MRD by using an off-the-shelf calibrator. Methods SILuMAB-based MS-MRD was performed by spiking a monoclonal stable isotope labeled IgG, SILuMAB-K1, in the patient serum. The abundance of both M-protein-specific peptides and SILuMAB-specific peptides were monitored by mass spectrometry. The relative ratio between M-protein peptides and SILuMAB peptides allowed for M-protein quantification. We assessed linearity, sensitivity and reproducibility of SILuMAB-based MS-MRD in longitudinally collected sera from the IFM-2009 clinical trial. Results A linear dynamic range was achieved of over 5 log scales, allowing for M-protein quantification down to 0.001 g/L. The inter-assay CV of SILuMAB-based MS-MRD was on average 11 %. Excellent concordance between SIL- and SILuMAB-based MS-MRD was shown ($ R^{2} $>0.985). Additionally, signal intensity of spiked SILuMAB can be used for quality control purpose to assess system performance and incomplete SILuMAB digestion can be used as quality control for sample preparation. Conclusions Compared to SIL peptides, SILuMAB-based MS-MRD improves the reproducibility, turn-around-times and cost-efficacy of MS-MRD without diminishing its sensitivity and specificity. Furthermore, SILuMAB can be used as a MS-MRD quality control tool to monitor sample preparation efficacy and assay performance..

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:62
Enthalten in:	Clinical chemistry and laboratory medicine - 62(2023), 3 vom: 12. Okt., Seite 540-550

Sprache:	Englisch

Beteiligte Personen:

Wijnands, Charissa [VerfasserIn] Langerhorst, Pieter [VerfasserIn] Noori, Somayya [VerfasserIn] Keizer-Garritsen, Jenneke [VerfasserIn] Wessels, Hans J.C.T. [VerfasserIn] Gloerich, Jolein [VerfasserIn] Bonifay, Vincent [VerfasserIn] Caillon, Hélène [VerfasserIn] Luider, Theo M. [VerfasserIn] van Gool, Alain J. [VerfasserIn] Dejoie, Thomas [VerfasserIn] VanDuijn, Martijn M. [VerfasserIn] Jacobs, Joannes F.M. [VerfasserIn]

Links:	Volltext [kostenfrei]

BKL:	44.46 / Klinische Pathologie

Anmerkungen:	© 2023 the author(s), published by De Gruyter, Berlin/Boston

doi:	10.1515/cclm-2023-0781

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	GRUY00942136X